Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to understand and provide signed and dated written consent.~2. Self-reported opioid use for nontherapeutic purposes on at least 21 days in the 30 days prior to screening, physical dependence on opioids, recent intravenous opioid use, and meeting DSM 5 criteria for moderate-severe opioid use disorder.~3. Positive urine drug screen for opioids (those who are in a methadone or buprenorphine treatment program are ineligible; physical dependence on street methadone or buprenorphine are also exclusionary so participants must produce at least one methadone- or buprenorphine-negative urine during screening).~4. ≥ 21 and ≤ 55 years of age.~5. Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2 and weight ≥ 50 kg (110 pounds).~6. Otherwise healthy as determined by the investigator.~7. Demonstrate understanding how to complete the self-administration tasks and VAS Questionnaire.~8. Women of childbearing potential must not be pregnant or breastfeeding at screening.~9. Willing and able to comply with all testing requirements defined in the protocol.~participation in the Study Treatment Phase:~1. During the Study Qualification Phase, on the bipolar 100--mm Drug Liking VAS, the subject must provide Emax ≥ 40 mm and \< 60 mm following placebo and, following morphine 56 mg/70 kg, i.v., Emax ≥ 60 mm and ≥ 15 mm closer to Strong Liking than the Emax to placebo.~2. In the judgment of the investigator, the subject is able to tolerate the i.v., opioids administered in the study, including the ability to complete most pharmacodynamics assessments administered post--dose.~3. In the judgment of the study staff, the subject's general behavior during the Study Qualification Phase suggests the ability to successfully complete the Study Treatment Phase.~Exclusion Criteria:~1. History of a medical or psychiatric disorder that would prevent successful completion of the study.~2. Current DSM-5 diagnosis of substance use disorders requiring medical management other than OUD.~3. Suicidal ideation or intent with or without a plan at Screening or within 6 months prior to Screening (i.e., answering Yes to questions 4 and/or 5 on the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale).~4. Currently seeking or participating in treatment for substance use disorder.~5. Physically dependent on drugs of abuse (other than opioids, nicotine, or caffeine) or alcohol.~6. Medically important deviation from normal limits on physical examination, vital signs, screening laboratory tests, or 12--lead ECG.~7. Significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, or neurologic disorder.~8. Any surgical, or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test drug.~9. Family history of long QT syndrome and/or unexpected sudden cardiac death or is known to have QTc \> 500 ms at screening.~10. Used an investigational agent within 30 days or 5 therapeutic half-lives of that agent, whichever is longer, prior to the first dose of study drug.~11. Hypersensitivity to opioids or any drug intended for use in this study.~12. Acute gastrointestinal symptoms (e.g., nausea, vomiting, fever, or Diarrhea unrelated to opioid withdrawal) ≤ 7 days before Day 1.~13. Any of the following values for laboratory tests at Screening:~    1. A positive pregnancy test in women of childbearing potential.~   2. Hemoglobin \< 11 g/dL in males and \< 10 gm/dL in females.~   3. Neutrophil count \< 1.0 × 109/L.~   4. Platelet count \< 75 × 109/L.~   5. Creatinine clearance \< 50 ml/min per modified Cockcroft-Gault equation.~   6. Aspartate aminotransferase or alanine aminotransferase \> 3.0x upper limit of normal.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous Challenge Drug: Oxymorphone (Type: ACTIVE_COMPARATOR): Intravenous (IV) Dose Range: 1.8, 3.2, 5.6, 10 mg/70kg of the participant's body weight
- Intravenous Challenge Drug: Oxycodone (Type: ACTIVE_COMPARATOR): IV Dose Range: 10, 18, 32, 56 mg/70kg of the participant's body weight
- Intravenous Challenge Drug: Hydromorphone (Type: ACTIVE_COMPARATOR): IV Dose Range: 3.2, 5.6, 10, 18 mg/70kg of the participant's body weight
- Intravenous Challenge Drug: Placebo (Type: PLACEBO_COMPARATOR): IV saline

Based on this trial design, predict the completion outcome and termination type (if applicable).